Goldman Sachs Group Inc. Sells 1,220,091 Shares of Catalent, Inc. (NYSE:CTLT)

Goldman Sachs Group Inc. reduced its position in shares of Catalent, Inc. (NYSE:CTLT) by 57.6% in the fourth quarter, Holdings Channel reports. The fund owned 897,944 shares of the company’s stock after selling 1,220,091 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Catalent were worth $40,345,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Gladius Capital Management LP bought a new stake in Catalent in the third quarter worth $28,000. GAMMA Investing LLC bought a new stake in Catalent in the fourth quarter worth $33,000. Cary Street Partners Investment Advisory LLC lifted its position in Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after buying an additional 709 shares during the last quarter. Rakuten Securities Inc. bought a new stake in Catalent in the fourth quarter worth $46,000. Finally, Federated Hermes Inc. bought a new stake in Catalent in the fourth quarter worth $46,000.

Insider Activity

In other news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.31% of the company’s stock.

Catalent Stock Performance

CTLT stock opened at $54.84 on Friday. The firm has a market cap of $9.92 billion, a price-to-earnings ratio of -8.99, a PEG ratio of 6.62 and a beta of 1.20. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $60.20. The business’s fifty day simple moving average is $55.51 and its two-hundred day simple moving average is $52.99.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CTLT. Stephens restated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, April 4th. StockNews.com assumed coverage on Catalent in a research report on Friday, June 14th. They issued a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $54.05.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.